Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Patients with stage IV NSCLC will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The dual primary objectives of this study are to assess the efficacy of durvalumab versus SoC in terms of OS (Overall Survival) in all randomized patients and in patients who are at low risk of EM (early mortality)
Age
18–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged at least 18 years
Documented evidence of Stage IV NSCLC
No sensitizing EGFR mutation and ALK rearrangement
PD-L1 high expression
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not be if
Prior chemotherapy or any other systemic therapy for advanced NSCLC
Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines
Brain metastases or spinal cord compression unless the patient is stable and off steroids for at least 14 days prior to start of study treatment
Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant
Active or prior documented autoimmune or inflammatory disorders (e.g., colitis or Crohn's disease\]
Clareo Health | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
